Literature DB >> 30372393

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery.

David F McDermott1, Michael Carducci1.   

Abstract

Entities:  

Year:  2018        PMID: 30372393      PMCID: PMC6299339          DOI: 10.1200/JCO.18.01198

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  67 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

3.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

4.  Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Authors:  Toni K Choueiri; James Larkin; Mototsugu Oya; Fiona Thistlethwaite; Marcella Martignoni; Paul Nathan; Thomas Powles; David McDermott; Paul B Robbins; David D Chism; Daniel Cho; Michael B Atkins; Michael S Gordon; Sumati Gupta; Hirotsugu Uemura; Yoshihiko Tomita; Anna Compagnoni; Camilla Fowst; Alessandra di Pietro; Brian I Rini
Journal:  Lancet Oncol       Date:  2018-03-09       Impact factor: 41.316

5.  Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.

Authors:  Shan-Shan Wang; Yi-Feng Gu; Nicholas Wolff; Karoliina Stefanius; Alana Christie; Anwesha Dey; Robert E Hammer; Xian-Jin Xie; Dinesh Rakheja; Ivan Pedrosa; Thomas Carroll; Renée M McKay; Payal Kapur; James Brugarolas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-30       Impact factor: 11.205

6.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

9.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Twenty-five years of mTOR: Uncovering the link from nutrients to growth.

Authors:  David M Sabatini
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.